Allele expression of Peroxisome-gamma2 proliferation activator receptor gene in overweight eldery patients with ischemic heart disease
- Authors: Folomeeva L.I1, Filippov E.V2
-
Affiliations:
- City clinical hospital № 29 of the Department of health of the city of Moscow
- Ryazan state medical University named after academician I.P. Pavlov
- Issue: Vol 16, No 3 (2021)
- Pages: 52-55
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/121968
- DOI: https://doi.org/10.23868/202110006
- ID: 121968
Cite item
Open Access
Access granted
Abstract
It is known that about a third of the world's population suffers from obesity. Peroxisome activation receptors, namely, the γ2 promoter, is abundantly locatein adipose tissue, regulating adipogenesis, lipid accumulation, and glucose homeostasis. The aim of this investigations was to study the expression features of the PPARγ2 gene alleles in elderly patients with comorbid conditions such as obesity and ischemic heart disease. From 2017 to 2019 in "Clinical Hospital № 29 named. N.E. Bauman” (Moscow) 140 patients of both sexes (54.3% men and 45.7% women) aged 60-89 years were examined by us. The main group included 70 pts with ischemic heart disease, and the control group included 70 pts without it. Pro12 allele carriage in the main group had 85%, and the Ala12 allele - 15%. Pro12Ala and Ala12Ala genotypes, Ala12 allele were detected more often in patients with ischemic heart disease than in the control group (p=0.0008 and p=0.0003, respectively). Pro12Ala genotypes carriage (OR=2.02, CI = 1.28-3.19, p=0.003) and Ala12Ala (OR=2.002, CI = 1.32-3.04, p=0.0006) of the Ala12 gene PPARγ2 increases the risk of developing ischemic heart disease by 2 times. The revealed features of the expression of PPARγ2 gene alleles in elderly patients with obesity and ischemic heart disease e confirm the ability of nuclear PPARs to control development, differentiation, metabolic homeostasis and reproduction. To clarify the role of various genotypes of the PPARy2 gene in the regulation of lipid metabolism and angiogenesis in the discussed comorbid conditions in elderly patients may help to identify new methods of it treatment.
Full Text
About the authors
L. I Folomeeva
City clinical hospital № 29 of the Department of health of the city of Moscow
Email: larisaigorevna.kudryavtseva@mail.ru
E. V Filippov
Ryazan state medical University named after academician I.P. Pavlov
References
- Soboleva N.P., Rudnev S.G., Nikolaev D.V. et al. Bioimpedance screening of the Russian population in health centers: prevalence of overweight and obesity.Russian med. J. 2014; 20(4): 4-13.
- Hales C.M., Carroll M.D., Fryar C.D. et al. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief 2017; 288: 1-8.
- McEwan I.J. The Nuclear Receptor Superfamily at Thirty. Met. Mol. Biol. 2016; 443: 3-9.
- Ivanova E.A., Parolari A., Myasoedova V. et al. Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery. J. Cardiol. 2015; 66(4): 271-8.
- Lamas Bervejillo M., Ferreira A.M. Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism. Adv. Exp. Med. Biol. 2019; 1127: 39-57.
- Janani C., Ranjitha Kumari B.D. PPAR gamma gene - a review. Diabetes Metab. Syndr. 2015; 9: 46-50.
- Derosa G., Sahebkar A., Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J. Cell. Physiol. 2018; 233(1): 153-61.
- Ivanova E.A., Myasoedova V.A, Melnichenko A.A. et al. Peroxisome Proliferator-ActivatedReceptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis. Curr. Pharm. Des. 2017; 23(7): 1119-24.
- Fukunaga Y., Itoh H., Doi K. et al. Thiazolidinediones, peroxisome proliferators-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001; 158: 113-9.
- Fujii M., Inoki I., Saga M. et al. Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferators-activated receptor gamma. J. Steroid Biochem. Mol. Biol. 2012; 1(29): 145-52.
- Wu Z., Lou Y., Jin W. et al. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma-2 gene (PPARy2) is associated with increased risk of coronary artery disease: a meta-analysis. PLoS One 2012; 7(12): e53105.
- Qu A., Shah Y.M., Manna S.K. et al. Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 65-73.
- Pischon T., Pai J., Manson J. et al. Peroxisome Proliferator-Activated Receptor- 2 P12A Polymorphism and Risk of Coronary Heart Disease in US Men and Women. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1654-8.
- Neifeld I.V., Bobyleva I.V., Skupova I.N. Risk factors of cardiovascular diseases in postmenopausal women depending on body mass index. Bulletin of medical Internet conferences 2012; 12: 1001-3.
- Sergeeva E.G., Berkovich O.A., Ionova Z.I. et al. Association of Peroxisome Proliferator-Activated Receptor- Gamma2 Pro12Ala Gene Variants with Insulinoresistance in Coronary Heart Disease Patients. J. Heart Stroke 2017; 2(1): 1016.
- Youssef S.M., Najaha М., Slimania А. et al. A Pro 12 Ala substitution in the PPARy2 polymorphism may decrease the number of diseased vessels and the severity of angiographic coronary artery. Coronary Artery Dis. 2013; 24 (5): 347-51.
Supplementary files
